Lifecore Biomedical (LFCR) Stock Forecast, Price Target & Predictions
LFCR Stock Forecast
Lifecore Biomedical stock forecast is as follows: an average price target of $6.50 (represents a 1.09% upside from LFCR’s last price of $6.43) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
LFCR Price Target
The average price target for Lifecore Biomedical (LFCR) is $6.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $5.00. This represents a potential 1.09% upside from LFCR's last price of $6.43.
LFCR Analyst Ratings
According to 2 Wall Street analysts, Lifecore Biomedical's rating consensus is 'Buy'. The analyst rating breakdown for LFCR stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lifecore Biomedical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 04, 2024 | Jacob Johnson | Stephens | $5.00 | $5.38 | -7.06% | -22.24% |
| Sep 05, 2024 | Matthew Hewitt | Craig-Hallum | $8.00 | $4.22 | 89.57% | 24.42% |
The latest Lifecore Biomedical stock forecast, released on Oct 04, 2024 by Jacob Johnson from Stephens, set a price target of $5.00, which represents a -7.06% decrease from the stock price at the time of the forecast ($5.38), and a -22.24% decrease from LFCR last price ($6.43).
Lifecore Biomedical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $6.50 | $6.50 |
| Last Closing Price | $6.43 | $6.43 | $6.43 |
| Upside/Downside | -100.00% | 1.09% | 1.09% |
In the current month, the average price target of Lifecore Biomedical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lifecore Biomedical's last price of $6.43. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 04, 2024 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Sep 05, 2024 | Craig-Hallum | - | Buy | Initialise |
Lifecore Biomedical's last stock rating was published by Stephens on Oct 04, 2024. The company gave LFCR a "Equal-Weight" rating, the same as its previous rate.
Lifecore Biomedical Financial Forecast
Lifecore Biomedical Revenue Forecast
| May 27 | Feb 27 | Nov 26 | Aug 26 | May 26 | Feb 26 | Nov 25 | Aug 25 | May 25 | Feb 25 | Nov 24 | Aug 24 | May 24 | Feb 24 | Nov 23 | Aug 23 | May 23 | Feb 23 | Nov 22 | Aug 22 | May 22 | Feb 22 | Nov 21 | Aug 21 | May 21 | Feb 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $31.55M | $27.60M | $38.80M | $43.35M | $47.63M | $53.07M | $129.49M | $53.07M | $139.83M | $135.64M | $130.90M | $137.78M | $156.13M | $138.71M |
| Avg Forecast | $45.60M | $42.91M | $37.67M | $32.85M | $41.81M | $39.30M | $33.08M | $28.11M | $39.36M | $34.74M | $29.75M | $23.19M | $35.02M | $35.77M | $30.24M | $24.54M | $29.05M | $28.00M | $43.00M | $42.74M | $45.86M | $48.41M | $131.68M | $129.12M | $124.58M | $135.46M | $134.37M | $127.38M | $155.99M | $148.67M |
| High Forecast | $46.49M | $43.74M | $38.40M | $33.48M | $42.62M | $40.06M | $33.72M | $28.66M | $40.12M | $35.41M | $30.32M | $23.64M | $35.09M | $36.46M | $30.83M | $24.66M | $29.61M | $28.54M | $43.83M | $43.37M | $46.54M | $49.14M | $133.65M | $131.04M | $126.44M | $137.48M | $136.37M | $129.28M | $158.32M | $150.89M |
| Low Forecast | $44.61M | $41.97M | $36.85M | $32.13M | $40.90M | $38.45M | $32.36M | $27.50M | $38.50M | $33.98M | $29.10M | $22.68M | $34.94M | $34.99M | $29.58M | $24.42M | $28.41M | $27.39M | $42.06M | $42.02M | $45.08M | $47.60M | $129.46M | $126.94M | $122.47M | $133.17M | $132.10M | $125.23M | $153.36M | $146.16M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.99% | 0.90% | 1.01% | 1.04% | 1.10% | 0.98% | 0.41% | 1.12% | 1.00% | 0.97% | 1.08% | 1.00% | 0.93% |
Lifecore Biomedical's average Quarter revenue forecast for Aug 23 based on 2 analysts is $24.54M, with a low forecast of $24.42M, and a high forecast of $24.66M. LFCR's average Quarter revenue forecast represents a -22.20% decrease compared to the company's last Quarter revenue of $31.55M (May 23).
Lifecore Biomedical EBITDA Forecast
| May 27 | Feb 27 | Nov 26 | Aug 26 | May 26 | Feb 26 | Nov 25 | Aug 25 | May 25 | Feb 25 | Nov 24 | Aug 24 | May 24 | Feb 24 | Nov 23 | Aug 23 | May 23 | Feb 23 | Nov 22 | Aug 22 | May 22 | Feb 22 | Nov 21 | Aug 21 | May 21 | Feb 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.60M | $-3.75M | $-3.88M | $-2.27M | $-3.30M | $6.12M | $2.44M | $6.12M | $11.21M | $1.02M | $-5.09M | $5.86M | $3.78M | $148.00K |
| Avg Forecast | $-2.92M | $-2.74M | $-2.41M | $-2.10M | $-2.67M | $-2.51M | $-2.12M | $-1.80M | $-2.52M | $-2.22M | $-1.90M | $-1.48M | $-2.24M | $-2.29M | $-1.93M | $-1.57M | $-1.86M | $-1.79M | $-2.75M | $133.24K | $142.96K | $150.93K | $410.53K | $402.53K | $388.38K | $422.29K | $418.91K | $397.12K | $486.32K | $463.49K |
| High Forecast | $-2.85M | $-2.68M | $-2.36M | $-2.05M | $-2.62M | $-2.46M | $-2.07M | $-1.76M | $-2.46M | $-2.17M | $-1.86M | $-1.45M | $-2.23M | $-2.24M | $-1.89M | $-1.56M | $-1.82M | $-1.75M | $-2.69M | $135.22K | $145.09K | $153.18K | $416.65K | $408.54K | $394.17K | $428.59K | $425.15K | $403.04K | $493.57K | $470.40K |
| Low Forecast | $-2.97M | $-2.80M | $-2.46M | $-2.14M | $-2.73M | $-2.56M | $-2.16M | $-1.83M | $-2.57M | $-2.26M | $-1.94M | $-1.51M | $-2.24M | $-2.33M | $-1.97M | $-1.58M | $-1.89M | $-1.83M | $-2.80M | $130.99K | $140.54K | $148.38K | $403.59K | $395.73K | $381.82K | $415.16K | $411.83K | $390.41K | $478.11K | $455.65K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.40% | 2.09% | 1.41% | -17.01% | -23.09% | 40.53% | 5.95% | 15.20% | 28.86% | 2.43% | -12.16% | 14.77% | 7.78% | 0.32% |
1 analysts predict LFCR's average Quarter EBITDA for May 22 to be $142.96K, with a high of $145.09K and a low of $140.54K. This is -97.66% lower than Lifecore Biomedical's previous annual EBITDA (Feb 22) of $6.12M.
Lifecore Biomedical Net Income Forecast
| May 27 | Feb 27 | Nov 26 | Aug 26 | May 26 | Feb 26 | Nov 25 | Aug 25 | May 25 | Feb 25 | Nov 24 | Aug 24 | May 24 | Feb 24 | Nov 23 | Aug 23 | May 23 | Feb 23 | Nov 22 | Aug 22 | May 22 | Feb 22 | Nov 21 | Aug 21 | May 21 | Feb 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-36.13M | $-15.46M | $-12.45M | $-12.06M | $-35.88M | $-7.11M | $-38.44M | $-7.11M | $-2.87M | $-11.00M | $-13.30M | $-5.50M | $-15.15M | $-4.78M |
| Avg Forecast | $-2.16M | $-4.63M | $-6.79M | $-10.18M | $-925.67K | $-4.47M | $-6.94M | $-9.57M | $102.84K | $-4.53M | $-8.95M | $-15.02M | $-3.70M | $-1.85M | $-6.48M | $-12.03M | $-13.73M | $-5.55M | $-6.48M | $-5.40M | $-848.53K | $308.56K | $-2.39M | $-4.57M | $-493.69K | $668.55K | $257.12K | $-4.06M | $-17.18M | $359.99K |
| High Forecast | $-2.10M | $-4.50M | $-6.60M | $-9.89M | $-899.43K | $-4.35M | $-6.75M | $-9.29M | $105.43K | $-4.40M | $-8.69M | $-14.59M | $-3.60M | $-1.80M | $-6.30M | $-6.02M | $-13.34M | $-5.40M | $-6.30M | $-5.28M | $-829.89K | $314.54K | $-2.34M | $-4.47M | $-482.85K | $681.51K | $262.10K | $-3.97M | $-16.80M | $366.97K |
| Low Forecast | $-2.21M | $-4.74M | $-6.96M | $-10.44M | $-948.95K | $-4.59M | $-7.12M | $-9.81M | $99.93K | $-4.64M | $-9.17M | $-15.39M | $-3.80M | $-1.90M | $-6.64M | $-18.05M | $-14.08M | $-5.69M | $-6.64M | $-5.50M | $-864.98K | $301.78K | $-2.44M | $-4.66M | $-503.26K | $653.87K | $251.47K | $-4.14M | $-17.51M | $352.09K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.63% | 2.78% | 1.92% | 2.23% | 42.29% | -23.03% | 16.08% | 1.56% | 5.81% | -16.45% | -51.73% | 1.35% | 0.88% | -13.29% |
Lifecore Biomedical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LFCR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Lifecore Biomedical SG&A Forecast
| May 27 | Feb 27 | Nov 26 | Aug 26 | May 26 | Feb 26 | Nov 25 | Aug 25 | May 25 | Feb 25 | Nov 24 | Aug 24 | May 24 | Feb 24 | Nov 23 | Aug 23 | May 23 | Feb 23 | Nov 22 | Aug 22 | May 22 | Feb 22 | Nov 21 | Aug 21 | May 21 | Feb 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.69M | $10.97M | $10.77M | $10.88M | $15.42M | $9.72M | $13.84M | $9.72M | $16.14M | $17.90M | $16.11M | $15.22M | $18.19M | $16.89M |
| Avg Forecast | $10.98M | $10.33M | $9.07M | $7.91M | $10.07M | $9.46M | $7.96M | $6.77M | $9.48M | $8.36M | $7.16M | $5.58M | $8.43M | $8.61M | $7.28M | $5.91M | $6.99M | $6.74M | $10.35M | $10.29M | $11.04M | $11.66M | $31.71M | $31.09M | $30.00M | $32.61M | $32.35M | $30.67M | $37.56M | $35.80M |
| High Forecast | $11.19M | $10.53M | $9.25M | $8.06M | $10.26M | $9.65M | $8.12M | $6.90M | $9.66M | $8.53M | $7.30M | $5.69M | $8.45M | $8.78M | $7.42M | $5.94M | $7.13M | $6.87M | $10.55M | $10.44M | $11.21M | $11.83M | $32.18M | $31.55M | $30.44M | $33.10M | $32.84M | $31.13M | $38.12M | $36.33M |
| Low Forecast | $10.74M | $10.11M | $8.87M | $7.74M | $9.85M | $9.26M | $7.79M | $6.62M | $9.27M | $8.18M | $7.01M | $5.46M | $8.41M | $8.42M | $7.12M | $5.88M | $6.84M | $6.59M | $10.13M | $10.12M | $10.85M | $11.46M | $31.17M | $30.56M | $29.49M | $32.06M | $31.81M | $30.15M | $36.93M | $35.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.67% | 1.63% | 1.04% | 1.06% | 1.40% | 0.83% | 0.44% | 0.31% | 0.54% | 0.55% | 0.50% | 0.50% | 0.48% | 0.47% |
Lifecore Biomedical's average Quarter SG&A projection for Aug 23 is $5.91M, based on 2 Wall Street analysts, with a range of $5.88M to $5.94M. The forecast indicates a -49.43% fall compared to LFCR last annual SG&A of $11.69M (May 23).
Lifecore Biomedical EPS Forecast
| May 27 | Feb 27 | Nov 26 | Aug 26 | May 26 | Feb 26 | Nov 25 | Aug 25 | May 25 | Feb 25 | Nov 24 | Aug 24 | May 24 | Feb 24 | Nov 23 | Aug 23 | May 23 | Feb 23 | Nov 22 | Aug 22 | May 22 | Feb 22 | Nov 21 | Aug 21 | May 21 | Feb 21 | Nov 20 | Aug 20 | May 20 | Feb 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.19 | $-0.51 | $-0.41 | $-0.41 | $-1.22 | $-0.24 | $-1.30 | $-0.24 | $-0.10 | $-0.38 | $-0.45 | $-0.19 | $-0.52 | $-0.16 |
| Avg Forecast | $-0.07 | $-0.15 | $-0.22 | $-0.33 | $-0.03 | $-0.14 | $-0.23 | $-0.31 | - | $-0.15 | $-0.29 | $-0.49 | $-0.12 | $-0.06 | $-0.21 | $-0.39 | $-0.45 | $-0.18 | $-0.21 | $-0.17 | $-0.03 | $0.01 | $-0.08 | $-0.15 | $-0.02 | $0.02 | $0.01 | $-0.13 | $-0.56 | $0.01 |
| High Forecast | $-0.07 | $-0.15 | $-0.21 | $-0.32 | $-0.03 | $-0.14 | $-0.22 | $-0.30 | - | $-0.14 | $-0.28 | $-0.47 | $-0.12 | $-0.06 | $-0.20 | $-0.20 | $-0.43 | $-0.17 | $-0.20 | $-0.17 | $-0.03 | $0.01 | $-0.08 | $-0.14 | $-0.02 | $0.02 | $0.01 | $-0.13 | $-0.54 | $0.01 |
| Low Forecast | $-0.07 | $-0.15 | $-0.23 | $-0.34 | $-0.03 | $-0.15 | $-0.23 | $-0.32 | - | $-0.15 | $-0.30 | $-0.50 | $-0.12 | $-0.06 | $-0.22 | $-0.58 | $-0.46 | $-0.18 | $-0.22 | $-0.18 | $-0.03 | $0.01 | $-0.08 | $-0.15 | $-0.02 | $0.02 | $0.01 | $-0.13 | $-0.57 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.67% | 2.83% | 1.95% | 2.34% | 44.36% | -24.00% | 16.77% | 1.62% | 6.11% | -17.54% | -54.00% | 1.44% | 0.93% | -13.71% |
According to undefined Wall Street analysts, Lifecore Biomedical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LFCR previous annual EPS of $NaN (undefined).
Lifecore Biomedical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TLRY | Tilray Brands | $1.32 | $7.42 | 462.12% | Hold |
| KMDA | Kamada | $5.95 | $20.00 | 236.13% | - |
| IRWD | Ironwood Pharmaceuticals | $4.02 | $11.67 | 190.30% | Buy |
| CTLT | Catalent | $58.78 | $74.25 | 26.32% | Hold |
| ALIM | Alimera Sciences | $5.54 | $5.75 | 3.79% | Hold |
| LFCR | Lifecore Biomedical | $6.43 | $6.50 | 1.09% | Buy |